semaglutide 2.4 mg weekly Dosing Wegovy 2.4 mg/0.75 mL pre-filled

Questions about treatment continuation

Gastrointestinal tolerability of once?weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss

Option 2: Consider the Approved Alternatives Two GLP-1 class medications are already approved in major markets

Effects of the novel (Pro3)GIP antagonist and exendin(939)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin

In a separate trial called ATTAIN-MAINTAIN, people who had been taking injectable GLP-1 medications like Wegovy or Zepbound were switched to Foundayo

The TrimRx Approach to Sustainable Health Our mission at TrimRx is to help you embrace a healthier lifestyle through science and empathy